A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects with Idiopathic Pulmonary Fibrosis (ATLAS)
Trial ID or NCT#
This study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in participants with Idiopathic Pulmonary Fibrosis (IPF) who had previously participated in Gilead clinical trial AB0024-201.
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToSusan Jacobs
Go Back To The Trial